LEQEMBI (lecanemab) Patient Assistance Program
Don’t let the high cost of brand specialty Alzheimer’s therapy stand between you and the treatment you need. We help eligible patients access Leqembi (lecanemab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing — Applying To LEQEMBI Companion Directly Is Always Free
- Paperwork, Documentation & Doctor-Coordination Handled For You
- Comprehensive Support: From Application To Entire Journey
- Annual Re-Certification And Renewals Management
- Medicare Part B Registry & Appeals Guidance — The Most Confusing Coverage Rules In Medicine
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Leqembi (Lecanemab) Is FDA-Approved For Early Alzheimer’s Disease — Mild Cognitive Impairment Or Mild Dementia With Confirmed Amyloid Pathology. It Is An Anti-Amyloid Antibody Given As An IV Infusion Every 2 Weeks, Or Now As Leqembi Iqlik, A Weekly At-Home Injection
- Leqembi’s List Price Is $26,500 Per Year For IV Treatment; The New Iqlik Subcutaneous Autoinjector Lists At $19,500 Per Year ($375 Per Weekly Injection). In July 2026 The FDA Approved Iqlik For Starting Treatment — Patients Can Now Begin At Home With No IV Phase At All.
- The LEQEMBI Companion Patient Assistance Program Provides Free Medication To Patients With Household Income At Or Below 300% Of The Federal Poverty Level Who Are Uninsured — Or Insured But Denied Coverage After Appeal. Commercially Insured Patients Can Get Up To $10,000 Per Year In Copay Support.
- Medicare Covers IV Leqembi Under Part B But Still Requires Enrollment In A CMS-Approved Registry, And Patients Without Supplemental Coverage Owe 20% Coinsurance — Roughly $5,300 Per Year. The $2,100 Part D Cap Does Not Apply To The IV Form.
What Is Leqembi Prescription Assistance Program?
The Leqembi Patient Assistance Program is part of LEQEMBI Companion, Eisai’s patient support hub, and provides Leqembi free of charge to qualifying patients: U.S. or Puerto Rico residents 18 or older with a valid on-label prescription, household income at or below 300% of the Federal Poverty Level, who are either uninsured or insured but denied coverage after at least a first-level appeal. Uninsured patients enroll on a rolling 12-month basis. Applying directly (1-833-4-LEQEMBI / 1-833-453-7362) is always free. But Leqembi’s real complexity isn’t the application — it’s the coverage maze around it: Medicare’s registry requirement, amyloid-confirmation documentation (PET, CSF, or the new FDA-cleared blood test), APOE4 genotyping and MRI-monitoring schedules, the appeal path when coverage is denied, and now the choice between IV and the at-home Iqlik injection, which are billed under entirely different benefits. For a flat $69.95 per month, our Patient Advocates manage all of it — for the patient and, just as often, for the family member coordinating their care.
Pharmacy Price Comparison
- Without assistance, Leqembi costs approximately $26,500/year at WAC, with per-infusion costs commonly $1,000+ at retail/specialty pricing. Pharmacy discount coupons are not a meaningful tool for IV therapy. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Per IV infusion (~70 kg) | ~$1,030.00 | Save ~$960/dose |
| Per IV infusion (~100 kg) | ~$1,470.00 | Save ~$1,400/dose |
| Bi-weekly schedule | ~$2,200/mo | Save ~$2,130/mo |
| Annual cost (WAC) | ~$26,500/yr | Save ~$25,500/yr |
| Required MRI monitoring | Add’l cost | Coordinated by us |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Leqembi Prescription Program?
The LEQEMBI Companion program is free to apply for and provides medication at no cost if approved. Our $69.95/month service covers full advocacy — and for Leqembi families, that usually means one person handling the registry, appeals, and renewals maze so the family can focus on care.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Leqembi:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $1,000–$1,500 per infusion per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Leqembi assistance.
- You Live In The U.S. Or Puerto Rico And Are 18 Or Older
- You Have A Valid On-Label Leqembi Prescription — Early Alzheimer’s With Confirmed Amyloid Pathology
- You Are Uninsured — Or Insured And Denied Coverage After At Least A First-Level Appeal
- Your Household Income Is At Or Below 300% Of The Federal Poverty Level
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Leqembi :
Leqembi binds soluble amyloid-beta protofibrils and amyloid plaques, flagging them for clearance by the brain’s immune cells. In its pivotal trial, that clearance translated into a measurable slowing of cognitive and functional decline over 18 months in early-stage patients. It is not a cure and does not reverse existing damage — which is exactly why timely diagnosis, coverage, and treatment start matter so much: the window for benefit is early.
How Leqembi Works:
Leqembi binds soluble amyloid-beta protofibrils and amyloid plaques, flagging them for clearance by the brain’s immune cells. In its pivotal trial, that clearance translated into a measurable slowing of cognitive and functional decline over 18 months in early-stage patients. It is not a cure and does not reverse existing damage — which is exactly why timely diagnosis, coverage, and treatment start matter so much: the window for benefit is early.
Form and Use:
The classic regimen is a 10 mg/kg IV infusion every 2 weeks. Since October 2025, patients on maintenance can switch to Leqembi Iqlik — a weekly subcutaneous autoinjector taking 1–2 minutes at home — and as of July 2026, the FDA approved Iqlik for starting treatment as well, meaning new patients can now begin therapy entirely without the IV phase. Beyond convenience, the form changes the billing: IV runs through the medical benefit (Medicare Part B, with infusion-center fees), while Iqlik is dispensed by specialty pharmacy through the pharmacy benefit. Treatment requires confirmed amyloid pathology — via PET scan, spinal-fluid testing, or the FDA-cleared blood test available since 2025 — plus baseline and periodic MRIs.
Generic Availability:
There is no generic or biosimilar lecanemab, and none is on any near-term horizon — the drug was approved in 2023 and holds long exclusivity. Its only in-class competitor is Kisunla (donanemab), a different antibody with different dosing. For cost purposes, assistance programs and insurance navigation are the only levers.
Warnings:
Leqembi carries a boxed warning for amyloid-related imaging abnormalities (ARIA) — brain swelling or micro-bleeds that are usually asymptomatic but can rarely be serious. Risk is higher in patients carrying two copies of the APOE4 gene (genotyping is recommended before starting) and in those on blood thinners. Treatment requires scheduled MRI monitoring; report headaches, confusion, dizziness, or vision changes promptly. Infusion-related reactions are common with the IV form and manageable.
FAQ (Frequently Asked Questions)
How Much Does Leqembi Cost Without Insurance
Eisai’s list price is $26,500 per year for IV treatment; the Iqlik at-home injection lists at $19,500 per year ($375 per weekly autoinjector). Patients at or below 300% of the Federal Poverty Level who are uninsured — or denied after appeal — can receive it free through LEQEMBI Companion; our $69.95 monthly fee covers full advocacy and enrollment management.
Does Medicare Cover Leqembi?
Yes — under Part B, with conditions: your prescriber must enroll you in a CMS-approved registry (still required in 2026), and amyloid pathology must be documented. Without supplemental coverage you owe 20% coinsurance — roughly $5,300 per year on the drug alone. A Medigap policy or Medicare Advantage out-of-pocket maximum is what actually protects most families; the $2,100 Part D cap does not apply to IV Leqembi.
What Is Leqembi Iqlik And Does It Change The Cost?
Iqlik is the subcutaneous autoinjector — weekly, at home, 1–2 minutes. FDA approved it for maintenance in 2025 and for starting treatment in July 2026, and it lists 26% below the IV form. Because it’s dispensed through specialty pharmacy rather than infused, it may run through the pharmacy benefit (Part D for Medicare patients, where the $2,100 cap applies) — but plan-level coverage varies, and we verify your specific plan before recommending a switch.
Do I Need A PET Scan To Start Leqembi?
Amyloid confirmation is required, but since 2025 there’s a cheaper path: the FDA cleared the first blood test for Alzheimer’s diagnosis, which can reduce the need for a $5,000+ PET scan or a spinal tap. Ask your neurologist what your insurance will accept — documentation strategy is part of what we coordinate.
Can I Get Copay Help If I Have Commercial Insurance?
Yes — Eisai’s copay program takes eligible commercially insured patients to as little as $0 per treatment, up to $10,000 per year. It cannot be used with any government insurance.
What If My Application Is Denied?
For Leqembi, a denial is not the end — it’s a doorway: Eisai’s assistance program explicitly accepts insured patients who were denied after a first-level appeal. That makes the appeal itself the critical step, and running it properly — with the right clinical documentation — is core to what our advocates do.
Take Control of Your Medication Costs
If you are struggling with the high cost of Leqembi, our team may be able to help you access assistance programs designed to make brand specialty Alzheimer’s therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.